drugset / Trial / NCT06108063

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

NCT06108063

Phase 1/2 Recruiting 120 enrolled Steadman Philippon Research Institute
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the efficacy of Losartan use post-operatively for reducing or preventing the development of arthrofibrosis and the associated adverse impacts on clinical outcomes.

Timeline

Start
2024-03-06
Primary completion
2027-06-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 12.5 mg Oral

Indications